Benefits
What the Cancer Trials Actually Found
Selenized yeast was the form used in the NPC (Nutritional Prevention of Cancer) trial. Its main goal, preventing skin cancer, was not met, and the secondary analyses that hinted at lower total and prostate cancer in men with low selenium were exploratory only. The much larger SELECT trial, which used L-selenomethionine rather than yeast, was stopped early and found no cancer benefit. Neither trial is among the studies cited on this page, and selenium is not shown to prevent cancer.
Diverse Selenoamino Acids
Selenium yeast contains selenomethionine (~70-90%) plus selenocysteine, selenocystathionine, methylselenocysteine, and small amounts of inorganic selenite — broader profile than pure selenomethionine. Theoretical advantage of yeast-derived nutritional matrix.
Food-Form Selenium
Sold as a 'food-form' selenium for people who prefer nutrients in a food matrix rather than isolated compounds. The one absorption study cited here (Hu 2011) found selenium yeast raised plasma selenium in human volunteers, but its effect on selenoprotein gene expression was limited, so a clear advantage over other selenium forms has not been demonstrated.
Standardization in Branded Forms
Standardized branded selenium yeasts — such as SelenoExcell® (Cypress Systems, used in the NPC trial) and SelenoPrecise® (Pharma Nord, used in the KiSel-10 trial) — have well-characterized selenium content and account for much of the published research. Generic selenium yeast products vary in how well they are standardized, and the amount and type of selenium can differ between products. See the dedicated branded profiles for trial details.
Raising Low Selenium Levels
In people whose selenium intake is low, selenium yeast raises blood selenium levels, which is what the human studies cited here measured. Most people eating a varied diet already get enough selenium, so more is not automatically better. Low selenium is something to confirm and manage with a doctor rather than self-treat.
Mechanism of action
Yeast Selenium Speciation
Saccharomyces cerevisiae grown in selenium-enriched media incorporates selenium into amino acids — converting methionine → selenomethionine via the methionine biosynthesis pathway. The resulting yeast contains ~70-90% selenomethionine plus minor selenoamino acids.
Broad Selenoprotein Support
Once digested and absorbed, selenium from yeast joins the body's pool of selenoamino acids and is used to build selenoproteins such as glutathione peroxidases, thioredoxin reductases, iodothyronine deiodinases and selenoprotein P. That selenium is required for these enzymes is basic biochemistry, but none of the studies cited on this page measured antioxidant status or immune function.
Yeast Nutritional Matrix
Whole yeast also supplies small amounts of B vitamins, beta-glucans and nucleotides. Whether these add anything on top of the selenium itself was not tested in any of the studies cited here.
Slow Selenium Release
Selenium built into yeast proteins has to be freed during digestion, so it is thought to be released more gradually than free selenomethionine or sodium selenite. This is a proposed difference rather than something the cited studies measured.
Clinical trials
Randomised, multiple-dose, placebo-controlled trial of selenium-enriched yeast at 100, 200 or 300 micrograms a day for five years, with deaths tracked for about ten years afterwards (Rayman MP, Winther KH et al., Free Radical Biology and Medicine 2018, PMID 29454039).
Adults living in a country with moderately low selenium status.
The authors concluded that 300 micrograms a day of selenium taken for five years in a country with moderately low selenium status increased all-cause mortality ten years later. That is the single most important finding on this page: it comes from a randomised trial, it used selenium yeast, and it points the wrong way. No dose improved survival. It is a strong argument against taking high-dose selenium long term, particularly if your diet already supplies enough.
Randomized, double-blind, placebo-controlled trial (n=1,312) of selenized yeast (200 µg/day) vs placebo for nonmelanoma skin cancer prevention. Secondary analyses examined other cancers.
1,312 patients with prior nonmelanoma skin cancer.
The primary skin-cancer endpoint was negative — selenium actually increased squamous-cell and total nonmelanoma skin cancer. Exploratory secondary findings suggested lower total/prostate cancer (mainly in low-selenium men), which generated enthusiasm and motivated SELECT. Later trials did not confirm any cancer prevention, and no cancer-prevention claim is supported. This trial is not among the studies cited in the reference list below.